

Hui-li Wong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9001753/publications.pdf>

Version: 2024-02-01

65
papers

3,811
citations

471371

17
h-index

168321

53
g-index

65
all docs

65
docs citations

65
times ranked

7589
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	6.0	1,872
2	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016, 8, 346ra92.	5.8	1,036
3	<i>NRG1</i> Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in <i>KRAS</i> Wild-Type Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4674-4681.	3.2	121
4	Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 135-146.	3.2	121
5	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	3.9	88
6	Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. <i>International Journal of Cancer</i> , 2016, 138, 671-678.	2.3	56
7	Real world outcomes in <i>KRAS</i> G12C mutation positive non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 310-317.	0.9	46
8	Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, e9-e15.	1.0	45
9	Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival. <i>Clinical Colorectal Cancer</i> , 2015, 14, 185-191.	1.0	42
10	Base excision repair deficiency signatures implicate germline and somatic <i>MUTYH</i> aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003681.	0.5	33
11	A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify <i>KRAS</i> Mutations in Clinical Specimens. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 214-227.	1.2	32
12	Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002329.	0.5	30
13	Impact of diabetes on clinicopathologic and genetic features of colorectal cancer formation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 426-426.	0.8	28
14	Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. <i>Clinical Cancer Research</i> , 2021, 27, 150-157.	3.2	24
15	Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, e569-e577.	1.0	23
16	Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia. <i>Journal of Geriatric Oncology</i> , 2015, 6, 387-394.	0.5	20
17	Docetaxel in very elderly men with metastatic castration-resistant prostate cancer. <i>Prostate International</i> , 2015, 3, 42-46.	1.2	18
18	Molecular characterization of <i>ERBB2</i> -amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002535.	0.5	16

#	ARTICLE	IF	CITATIONS
19	Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. <i>Journal of Cancer Epidemiology</i> , 2015, 2015, 1-8.	0.5	13
20	Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 196-201.	0.6	12
21	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. <i>Internal Medicine Journal</i> , 2019, 49, 446-454.	0.5	12
22	Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1889-1897.	1.9	10
23	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. <i>Pharmacoeconomics</i> , 2020, 38, 683-713.	1.7	10
24	Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 11015-11015.	0.8	10
25	Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2017, 16, e45-e54.	1.0	9
26	Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 1155-1165.	1.3	9
27	Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent. <i>Clinical Colorectal Cancer</i> , 2016, 15, e125-e132.	1.0	8
28	CD8 ⁺ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous <i>de novo</i> metastatic colorectal carcinoma do not track with survival. <i>Clinical and Translational Immunology</i> , 2020, 9, e1155.	1.7	8
29	The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 314-321.	0.7	7
30	Previous Bevacizumab and Efficacy of Later Anti-EGFR Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. <i>Clinical Colorectal Cancer</i> , 2018, 17, e593-e599.	1.0	6
31	Tumor burden (TB) as a prognostic indicator in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 572-572.	0.8	5
32	A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3518-3518.	0.8	5
33	Risk-Adjusted Pathologic Margin Positivity Rate: A Problematic Quality Indicator. <i>Journal of Clinical Oncology</i> , 2015, 33, 1410-1411.	0.8	4
34	Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies. <i>Visceral Medicine</i> , 2020, 36, 388-396.	0.5	4
35	Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. <i>Clinical Colorectal Cancer</i> , 2021, 20, e21-e34.	1.0	4
36	Vandetanib for the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2271-2278.	0.9	3

#	ARTICLE	IF	CITATIONS
37	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. <i>Pharmacoeconomics</i> , 2020, 38, 1263-1275.	1.7	3
38	Demonstrating the feasibility of collecting secondary, deidentified data on Australian patients receiving treatment as part of a Medicine Access Programme. <i>Internal Medicine Journal</i> , 2020, 50, 99-104.	0.5	2
39	Real-world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma. <i>ANZ Journal of Surgery</i> , 2022, 92, 1789-1796.	0.3	2
40	Problematic Use of Multiple Subgroup Analyses in Assessing the Impact of Aspirin in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2226-2226.	0.8	1
41	Massively parallel sequencing (MPS) of circulating DNA in patients with metastatic colorectal cancer (mCRC): Prognostic significance and early changes during chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11015-11015.	0.8	1
42	Patterns of care of elderly patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14640-e14640.	0.8	1
43	Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC)?. <i>Journal of Clinical Oncology</i> , 2013, 31, 410-410.	0.8	1
44	Safety and efficacy of bevacizumab and systemic therapy in metastatic colorectal cancer (mCRC) patients with peritoneal disease in the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 569-569.	0.8	1
45	Treatment sequencing and outcomes in synchronous metastatic rectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 750-750.	0.8	1
46	Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15753-e15753.	0.8	1
47	Left- versus right-side metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, 623-623.	0.8	1
48	Metastatic colorectal cancer and management in public versus private hospitals: Similarities and differences.. <i>Journal of Clinical Oncology</i> , 2013, 31, 497-497.	0.8	1
49	Metastatic colorectal cancer (mCRC) with primary in situ: An Australian registry.. <i>Journal of Clinical Oncology</i> , 2013, 31, 498-498.	0.8	1
50	Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 386-386.	0.8	1
51	Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 468-468.	0.8	1
52	Clinicopathological features of pancreatic cancer-related diabetes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 675-675.	0.8	1
53	Characteristics and outcomes of participants in colorectal cancer biomarker trials versus a real-world cohort. <i>Acta Oncologica</i> , 2021, 60, 482-490.	0.8	1
54	Complete metabolic response following anaplastic lymphoma kinase (ALK) targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence in situ hybridisation discordant ALK test results. <i>Internal Medicine Journal</i> , 2021, 51, 1355-1356.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?. <i>Journal of Clinical Oncology</i> , 2013, 31, 534-534.	0.8	0
56	Aspirin use and survival outcomes in patients (pts) with PIK3CA mutant colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 3598-3598.	0.8	0
57	Understanding why some people with stage III colon cancer do not receive adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14608-e14608.	0.8	0
58	Primary tumor resection in metastatic colorectal cancer (mCRC): A prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3584-3584.	0.8	0
59	Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?. <i>Journal of Clinical Oncology</i> , 2013, 31, e14583-e14583.	0.8	0
60	Are the survival benefits associated with primary resection in de novo metastatic colorectal cancer (mCRC) mediated by reversal of systemic inflammation?. <i>Journal of Clinical Oncology</i> , 2014, 32, 464-464.	0.8	0
61	Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 273-273.	0.8	0
62	Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16124-e16124.	0.8	0
63	Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. <i>Growth Factors</i> , 2020, 38, 127-136.	0.5	0
64	Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	0.7	0
65	Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei. <i>European Journal of Surgical Oncology</i> , 2022, , .	0.5	0